Butyrophilin 3A1 Contributes to Inflammation and Induces a Lupus-Like Disease by Inhibiting the IL-38-Ferroptosis Axis

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. Recent evidence has linked butyrophilin 3A1 (BTN3A1) to immune dysregulation. This study was to elucidate the relationship of BTN3A1 in SLE. Expression of BTN3A1 in plasma and peripheral blood mononuclear cells from SLE patients and healthy controls explored the association between BTN3A1 and SLE. We found that BTN3A1 mRNA, plasma levels, and expression in CD4⁺ T cells were significantly elevated in SLE patients. In BTN3A1 gene knock-in (BTN3A1^KI) mice, inflammation and lupus-like manifestations occurred, including increased proportions of Th1, Th2, and Th17 cells, decreased Treg cells, elevated levels of inflammatory cytokines and anti-dsDNA antibodies, renal injury, and suppressed IL-38 serum levels. Intraperitoneal injection of IL-38 in pristane-treated BTN3A1^KI mice notably alleviated these pathological changes. Mechanistic investigations revealed that CD4⁺ T cells and the ferroptosis pathway were closely associated with the effects mediated by the BTN3A1-IL-38 axis. In vitro experiments showed that IL-38 stimulation reduced proliferation, apoptosis, and decreased the expression of ferroptosis-related proteins, Fe²⁺, glutathione, and malondialdehyde in CD4⁺BTN3A1^+/+ T and BTN3A1^+/+ Jurkat T cells. Overall, BTN3A1 plays a crucial role in SLE pathogenesis by regulating CD4⁺ T cell function.

Keywords

butyrophilin 3A1 / IL-38 / inflammation / lupus

References

[1] H. Li, A. Boulougoura, and Y. Endo, “Abnormalities of T Cells in Systemic Lupus Erythematosus: New Insights in Pathogenesis and Therapeutic Strategies,” Journal of Autoimmunity 132 (2022): 102870.

[2] A. Suárez-Fueyo, S. J. Bradley, and D. Klatzmann, “T Cells and Autoimmune Kidney Disease,” Nature Reviews Nephrology 13, no. 6 (2017): 329-343.

[3] V. R. Moulton, A. Suarez-Fueyo, and E. Meidan, “Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective,” Trends in Molecular Medicine 23, no. 7 (2017): 615-635.

[4] Y. Fan, K. Ma, and Y. Lin, “Immune Imbalance in Lupus Nephritis: The Intersection of T-Cell and Ferroptosis,” Frontiers in Immunology 15 (2024): 1520570.

[5] A. S. Kone, S. Ait Ssi, S. Sahraoui, and A. Badou, “BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment,” International Journal of Molecular Sciences 23, no. 21 (2022): 13424.

[6] C. Le Page, A. Marineau, and P. K. Bonza, “BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated With Higher Tumor Infiltrating T Cells and a Better Prognosis,” PLoS ONE 7, no. 6 (2012): e38541.

[7] J. R. Cubillos-Ruiz, D. Martinez, and U. K. Scarlett, “CD277 is a Negative Co-Stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells,” Oncotarget 1, no. 5 (2010): 329-338.

[8] M. M. Karunakaran and T. Herrmann, “The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T Cells,” Frontiers in Immunology 5 (2014): 648.

[9] A. Sandstrom, C. M. Peigné, and A. Léger, “The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells,” Immunity 40, no. 4 (2014): 490-500.

[10] T. Herrmann and M. M. Karunakaran, “Butyrophilins: Γδ T Cell Receptor Ligands, Immunomodulators and More,” Frontiers in Immunology 13 (2022): 876493.

[11] A. S. Kone, A. Ghouzlani, and A. Qandouci, “High Expression of BTN3A1 Is Associated With Clinical and Immunological Characteristics and Predicts a Poor Prognosis in Advanced Human Gliomas,” Frontiers in Immunology 15 (2024): 1397486.

[12] Y. Yang, L. Li, and L. Yuan, “A Structural Change in Butyrophilin Upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation,” Immunity 50, no. 4 (2019): 1043-1053.

[13] M. Wu, J. Liu, and L. Liu, “Autologous Peripheral Vγ9Vδ2 T Cell Synergizes With Αβ T Cell through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer,” Advanced Science 12, no. 18 (2025): e2401230.

[14] M. Seo, S. O. Lee, and J. H. Kim, “MAP4-Regulated Dynein-Dependent Trafficking of BTN3A1 Controls the TBK1-IRF3 Signaling Axis,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 50 (2016): 14390-14395.

[15] N. Messal, E. Mamessier, and A. Sylvain, “Differential Role for CD277 as a Co-Regulator of the Immune Signal in T and NK Cells,” European Journal of Immunology 41, no. 12 (2011): 3443-3454.

[16] J. Zhou, J. Zhang, and L. Tao, “Up-Regulation of BTN3A1 on CD14+ Cells Promotes Vγ9Vδ2 T Cell Activation in Psoriasis,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 44 (2022): e2117523119.

[17] M. Zhu, K. Xu, and Y. Chen, “Identification of Novel T1D Risk Loci and Their Association with Age and Islet Function at Diagnosis in Autoantibody-Positive T1D Individuals: Based on a Two-Stage Genome-Wide Association Study,” Diabetes Care 42, no. 8 (2019): 1414-1421.

[18] W. D. Xu, C. Yang, and R. Li, “Association of BTN3A1 Gene Polymorphisms With Systemic Lupus Erythematosus in a Chinese Han Population,” International Journal of Rheumatic Diseases 27, no. 3 (2024): e15112.

[19] M. A. Boutet , A. Najm , and G. Bart , “IL-38 Overexpression Induces Anti-Inflammatory Effects in Mice Arthritis Models and in Human Macrophages in Vitro,” Annals of the Rheumatic Diseases 76, no. 7 (2017): 1304-1312.

[20] X. Sun, T. Hou, and E. Cheung, “Anti-Inflammatory Mechanisms of the Novel Cytokine Interleukin-38 in Allergic Asthma,” Cellular & Molecular Immunology 17, no. 6 (2020): 631-646.

[21] W. D. Xu, L. C. Su, and X. Y. Liu, “IL-38: A Novel Cytokine in Systemic Lupus Erythematosus Pathogenesis,” Journal of Cellular and Molecular Medicine 24, no. 21 (2020): 12379-12389.

[22] W. D. Xu, L. C. Su, and L. Fu, “IL-38, a Potential Therapeutic Agent for Lupus, Inhibits Lupus Progression,” Inflammation Research 71, no. 7-8 (2022): 963-975.

[23] Z. Wu, Q. Lamao, and M. Gu, “Unsynchronized Butyrophilin Molecules Dictate Cancer Cell Evasion of Vγ9Vδ2 T-Cell Killing,” Cellular & Molecular Immunology 21, no. 4 (2024): 362-373.

[24] M. Akiyama, W. Alshehri, K. Yoshimoto, and Y. Kaneko, “T Follicular Helper Cells and T Peripheral Helper Cells in Rheumatic and Musculoskeletal Diseases,” Annals of the Rheumatic Diseases 82, no. 11 (2023): 1371-1381.

[25] C. H. Siegel, and L. R. Sammaritano, “Systemic Lupus Erythematosus: A Review,” JAMA 331, no. 17 (2024): 1480-1491.

[26] K. K. Payne, J. A. Mine, and S. Biswas, “BTN3A1 Governs Antitumor Responses by Coordinating Αβ and Γδ T Cells,” Science 369, no. 6506 (2020): 942-949.

[27] M. Doglio, A. Ugolini, and C. Bercher-Brayer, “Regulatory T Cells Expressing CD19-targeted Chimeric Antigen Receptor Restore Homeostasis in Systemic Lupus Erythematosus,” Nature Communications 15, no. 1 (2024): 2542.

[28] L. Xie, Z. Huang, H. Li, X. Liu, S. Zheng, and W. Su, “IL-38: A New Player in Inflammatory Autoimmune Disorders,” Biomolecules 9, no. 8 (2019): 345.

[29] L. Liu, T. K. Hitchens, and Q. Ye, “Decreased Reticuloendothelial System Clearance and Increased Blood Half-Life and Immune Cell Labeling for Nano- and Micron-Sized Superparamagnetic Iron-Oxide Particles Upon Pre-Treatment With Intralipid,” Biochimica Et Biophysica Acta 1830, no. 6 (2013): 3447-3453.

[30] Q. Cheng, L. Mou, and W. Su, “Ferroptosis of CD163+ Tissue-Infiltrating Macrophages and CD10+ PC+ Epithelial Cells in Lupus Nephritis,” Frontiers in Immunology 14 (2023): 1171318.

[31] P. Li, M. Jiang, and K. Li, “Glutathione Peroxidase 4-Regulated Neutrophil Ferroptosis Induces Systemic Autoimmunity,” Nature Immunology 22, no. 9 (2021): 1107-1117.

[32] K. Tenbrock and T. Rauen, “T Cell Dysregulation in SLE,” Clinical Immunology 239 (2022): 109031.

[33] H. N. Bell, B. R. Stockwell, and W. Zou, “Ironing out the Role of Ferroptosis in Immunity,” Immunity 57, no. 5 (2024): 941-956.

[34] S. Lu, X. Wei, and H. Zhu, “m6A Methyltransferase METTL3 Programs CD4+ T-Cell Activation and Effector T-Cell Differentiation in Systemic Lupus Erythematosus,” Molecular Medicine 29, no. 1 (2023): 46.

[35] X. Gao, Y. Song, and J. Wu, “Iron-Dependent Epigenetic Modulation Promotes Pathogenic T Cell Differentiation in Lupus,” Journal of Clinical Investigation 132, no. 9 (2022): e152345.

[36] M. Lai, H. Peng, X. Wu, et al., “IL-38 in Modulating Hyperlipidemia and Its Related Cardiovascular Diseases,” International Immunopharmacology 108 (2022): 108876.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.